1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lilly’s Mirikizumab Shows Superiority Vs. Cosentyx In Psoriasis

 
• By Joseph Haas

Lilly plans to file the anti-IL-23 antibody for approval in psoriasis based on two Phase III trials. The latest data head-to-head against IL-17 inhibitor Cosentyx may guide physicians on how to treat patients.

Two female fencing athletes fight on professional sports arena with spectators and lense-flares. Women wear unbranded sports clothes.
Lilly's mirikizumab showed superiority versus Consentyx in three 52-week measures

Eli Lilly and Company is ready to file its interleukin-23 inhibitor mirikizumab with the US Food and Drug Administration for approval in moderate-to-severe plaque psoriasis after reporting results from a second successful Phase III study on 17 July. The OASIS-2 trial showed that the candidate was non-inferior to the interleukin-17 inhibitor Cosentyx (secukinumab) on three endpoints at 16 weeks and superior to Novartis AG’s market-leading biologic at 52 weeks on those same endpoints.

Lilly already has its own IL-17 therapy, Taltz (ixekizumab), on the market for psoriasis but the company’s strategy is to give clinicians a number of therapeutic options since psoriasis is a chronic condition and many patients cycle through various therapies,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.